Skip to main content

Advertisement

SpringerLink
Log in

Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)

  • Case Report
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

We report a patient with HER2-positive breast cancer with extensive bone metastasis who achieved excellent and durable response with oral etoposide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  CAS  Google Scholar 

  2. Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.

    Article  CAS  Google Scholar 

  3. Johnston SRD, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: alternative. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:741–8.

    Article  CAS  Google Scholar 

  4. Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.

    Article  CAS  Google Scholar 

  5. Freedman RA, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:1081–9.

    Article  CAS  Google Scholar 

  6. Bang YJ, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:855–61.

    CAS  Google Scholar 

  7. Phillips NC. Oral etoposide. Drug Intell Clin Pharm. 1988;22:860–3.

    Article  CAS  Google Scholar 

  8. Panigrahy D, et al. Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med. 2010;1:739–46.

    Article  CAS  Google Scholar 

  9. Cabel L, et al. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. Breast Cancer Res Treat. 2019;173:397–406.

    Article  CAS  Google Scholar 

  10. Cameron D, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet Lond Engl. 2017;389:1195–205.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Institute (WIA), 38, Sardar Patel Road, Chennai, Tamil Nadu, 600036, India

    Manikandan Dhanushkodi

  2. Radiation Oncology, Cancer Institute (WIA), Chennai, India

    Priya Iyer & Balasubramanian Ananthi

  3. Surgical Oncology, Cancer Institute (WIA), Chennai, India

    Arvind Krishnamurthy

  4. Nuclear Medicine, Cancer Institute (WIA), Chennai, India

    K. M. Lakshmipathy

Authors
  1. Manikandan Dhanushkodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Priya Iyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Balasubramanian Ananthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arvind Krishnamurthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. M. Lakshmipathy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manikandan Dhanushkodi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhanushkodi, M., Iyer, P., Ananthi, B. et al. Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC). Indian J Gynecol Oncolog 17, 65 (2019). https://doi.org/10.1007/s40944-019-0311-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-019-0311-4

Keywords

Search

Navigation